Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466205 | 0.92 | CHRM1 (0.59) | CHRM1TBK1TP53THRBMAPT | |
| SCHEMBL3466011 | 0.83 | CHRM1 (0.56) | CHRM1MEN1ALDH1A1KMT2A | |
| SCHEMBL3465898 | 0.82 | CHRM1 (0.50) | CHRM1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL3466812 | 0.82 | CHRM1 (0.50) | CHRM1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL29800401 | 0.82 | CHRM1 (0.47) | CHRM1MAPTALDH1A1 | |
| SCHEMBL29800550 | 0.80 | CHRM1 (0.46) | CHRM1MAPTALDH1A1 | |
| SCHEMBL3467778 | 0.80 | CHRM1 (0.53) | CHRM1MEN1KMT2A | |
| SCHEMBL3198529 | 0.78 | CHRM1 (0.63) | CHRM1MAPTALDH1A1KMT2A | |
| SCHEMBL3198416 | 0.78 | CHRM1 (0.63) | CHRM1MAPTALDH1A1KMT2A | |
| SCHEMBL3195648 | 0.77 | CHRM1 (0.63) | CHRM1IDO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678791-B2 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE IP VENTURES, L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | CHRM1 4498/4885GLS 482/4885TBK1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.